Live Quote · NASDAQALTHealthcare · Biotechnology

Altimmune, Inc.

$2.73▲ 3.60%(+$0.10)

TickerSpark Score

59/100

▌ Mixed

60

Valuation

20

Profitability

100

Growth

84

Health

30

Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALT research report →

52-Week Range3% of range

Low

$2.56

Current

$2.73

High

$7.73

Company Overviewaltimmune.com

About the company

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist.

CEO: Jerome Benedict Durso
IPO: 2017
Employees: 59
HQ: Gaithersburg, MD, US

Price Chart

-59.51% · this period

Valuation

Market Cap: $241.38M
P/E: -3.74
P/S: 6705.10
P/B: 1.20
EV/EBITDA: -2.03
Div Yield: 0.00%

Profitability

Gross Margin: -41519.44%
Op Margin: -269216.67%
Net Margin: -253002.78%
ROE: -42.57%
ROIC: -29.86%

Growth & Income

Revenue: $41.00K · 105.00%
Net Income: $-88,093,000 · 7.33%
EPS: $-1.00 · 25.37%
Op Income: $-94,489,000
FCF YoY: 15.41%

Performance & Tape

52W High: $7.73
52W Low: $2.56
50D MA: $2.98
200D MA: $3.89
Beta: 0.23
Avg Volume: 3.81M

Get TickerSpark's AI analysis on ALT

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

Date	Insider	Role	Type	Shares	Value
May 1, 26	Lawver Teri L	director	other	48,800	$137.62K
May 1, 26	Sohn Catherine A.	director	other	48,800	$137.62K
May 1, 26	Jorkasky Diane	director	other	48,800	$137.62K
May 1, 26	Schafer Klaus	director	other	48,800	$137.62K
May 1, 26	Pisano Wayne	director	other	48,800	$137.62K
May 1, 26	Hodges Philip	director	other	48,800	$137.62K
May 1, 26	GILL JOHN	director	other	48,800	$137.62K
May 1, 26	SAYARE MITCHEL	director	other	48,800	$137.62K
Apr 6, 26	GILL JOHN	director	buy	9,200	$31.35K
Apr 1, 26	WEAVER GREGORY L	officer: Chief Financial Officer	buy	10,000	$31.50K

Coverage · ALT

Our ALT coverage

Recent articles, reports, and earnings notes.

View all →

IPO

Should You Buy the Palatin Technologies IPO? Here's the Setup

Palatin Technologies, Inc. (NASDAQ: PTN) is expected to list on May 29, 2026, but the price range has not been disclosed. The company is not a traditional IPO: it is a long-public biotech moving to Nasdaq via a resale registration tied to warrant exercises. The bull case is pipeline leverage in obesity and rare disease; the bear case is dilution, losses, and a very tight cash position.